Aripiprazole in Children With Autism: A Pilot Study

Completed · Phase 2

Conditions studied: Autism

In brief

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism. Children who qualify for the study will be treated with aripiprazole for 6 weeks. Treatment is provided at no cost.

Key facts

Study ID

NCT00208533

Run by

Drexel University College of Medicine

People needed

11

Starts

2004-02-01

Expected to finish

2011-11-16

Last updated by the study team

2018-07-30

Who can join

Age: 12 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.
• Males and females.
• Aged 12 to 18 years.
• Clinical judgment that medication treatment for autism is indicated.

You may not qualify if…

• Major medical problems including cardiac, liver, endocrine, or renal diseases.
• Uncontrolled seizures.
• Baseline QTC greater than 425 msec.
• Concomitant treatment with psychotropic medication.
• History of prior exposure to aripiprazole.

Where it is running

• Drexel University College of Medicine at Friends Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.